NFE2L2 and cancer: While the activation of Keap1/Nrf2/ARE pathway by CDDO and its derivatives has been shown to be beneficial in several experimental models of human diseases, such as neurodegenerative diseases [30,31,41,42,43,44], eye diseases [45,46], and lung pathologies [47,48], the lines of evidence of a possible effect on cancer development are less convincing.